Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BI 836858 + Decitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BI 836858||BI836858||CD33 Antibody 11||BI 836858 is a human antibody against CD33 that induces cytotoxic immune response against CD33-positive tumor cells (PMID: 27013443).|
|Decitabine||Dacogen||5-aza-2-deoxycytidine||DNMT inhibitor (Pan) 5||Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||BI 836858 + Decitabine||Preclinical - Patient cell culture||Actionable||In a preclinical study, treatment of patient derived acute myeloid leukemia blast cells with Dacogen (decitabine) enhanced BI 836858-mediated cytotoxic immune response in culture (PMID: 27013443).||27013443|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02632721||Phase II||BI 836858 + Decitabine Decitabine||A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)||Active, not recruiting|